Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters








Publication year range
1.
Int J Antimicrob Agents ; 38(1): 60-4, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21530184

ABSTRACT

The aim of this study was to compare the pharmacokinetics and efficacy of ciprofloxacin as post-exposure therapy against inhalational anthrax in the common marmoset (Callithrix jacchus) with other non-human primate models in order to determine whether the marmoset is a suitable model to test post-exposure therapies for anthrax. Pharmacokinetic (PK) and efficacy studies with ciprofloxacin were performed in the marmoset. Ciprofloxacin plasma pharmacokinetics were determined in six animals in separate single-dose and multiple-dose studies and were analysed by high-performance liquid chromatography (HPLC). A separate group of marmosets was exposed to ca. 100× the 50% lethal dose (LD(50)) of Bacillus anthracis Ames strain by the airborne route. On Day 5 of a twice-daily dosing regimen of 17.5 mg/kg, the ciprofloxacin half-life (t(1/2)), maximum drug concentration (C(max)) and area under the concentration-time curve (AUC) in marmoset plasma were 1.9 h, 2.1 µg/mL and 7.9 µg/mL/h, respectively. Naïve untreated control animals succumbed to infection by Day 9. All animals treated with ciprofloxacin, started on the day of exposure and continued for 10 days, remained healthy during the treatment period. Two antibiotic-treated animals (33%) died after withdrawal of antibiotic therapy, attributed to the germination of residual spores. In conclusion, in many respects the marmoset appears to respond to B. anthracis in a similar way to the macaque, suggesting that this small non-human primate is an acceptable, practical alternative model for the evaluation of medical countermeasures against respiratory anthrax infection.


Subject(s)
Anthrax/drug therapy , Anti-Bacterial Agents/therapeutic use , Callithrix , Ciprofloxacin/therapeutic use , Disease Models, Animal , Inhalation Exposure , Respiratory Tract Infections/drug therapy , Animals , Anthrax/microbiology , Anthrax/mortality , Anthrax/pathology , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/pharmacology , Bacillus anthracis/drug effects , Bacillus anthracis/pathogenicity , Ciprofloxacin/pharmacokinetics , Ciprofloxacin/pharmacology , Female , Humans , Male , Respiratory Tract Infections/microbiology , Respiratory Tract Infections/mortality , Respiratory Tract Infections/pathology , Spores, Bacterial/drug effects
2.
Clin Vaccine Immunol ; 16(5): 779-83, 2009 May.
Article in English | MEDLINE | ID: mdl-19321692

ABSTRACT

There is a need to identify vaccines that can protect against Brucella, a potential bioterrorism agent. We have developed mouse models of infection with aerosolized Brucella melitensis and Brucella suis and demonstrated their utility for the evaluation of vaccines using the model live B. melitensis vaccine strain Rev.1.


Subject(s)
Brucella melitensis/immunology , Brucella suis/immunology , Brucellosis/microbiology , Brucellosis/prevention & control , Aerosols , Animals , Brucella Vaccine/immunology , Disease Models, Animal , Humans , Mice , Mice, Inbred BALB C
3.
Int J Exp Pathol ; 90(1): 16-25, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19200247

ABSTRACT

Burkholderia pseudomallei is the causative agent of melioidosis, which is considered a potential deliberate release agent. The objective of this study was to establish and characterise a relevant, acute respiratory Burkholderia pseudomallei infection in BALB/c mice. Mice were infected with 100 B. pseudomallei strain BRI bacteria by the aerosol route (approximately 20 median lethal doses). Bacterial counts within lung, liver, spleen, brain, kidney and blood over 5 days were determined and histopathological and immunocytochemical profiles were assessed. Bacterial numbers in the lungs reached approximately 10(8) cfu/ml at day 5 post-infection. Bacterial numbers in other tissues were lower, reaching between 10(3) and 10(5) cfu/ml at day 4. Blood counts remained relatively constant at approximately 1.0 x 10(2) cfu/ml. Foci of acute inflammation and necrosis were seen within lungs, liver and spleen. These results suggest that the BALB/c mouse is highly susceptible to B. pseudomallei by the aerosol route and represents a relevant model system of acute human melioidosis.


Subject(s)
Burkholderia pseudomallei/pathogenicity , Disease Models, Animal , Melioidosis/microbiology , Respiratory Tract Infections/microbiology , Acute Disease , Aerosols , Animals , Burkholderia pseudomallei/growth & development , Burkholderia pseudomallei/isolation & purification , Colony Count, Microbial , Female , Hepatitis, Animal/microbiology , Hepatitis, Animal/pathology , Lung/microbiology , Lung/pathology , Melioidosis/pathology , Mice , Mice, Inbred BALB C , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/pathology , Respiratory Tract Infections/pathology , Virulence
4.
Infect Immun ; 77(4): 1315-23, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19188359

ABSTRACT

Presently there is a significant effort to develop and evaluate vaccines and antibiotics against the potential bioterrorism agent Yersinia pestis. The animal models used to test these countermeasures involve the deposition of small particles within the lung. However, deliberate aerosol release of Y. pestis will generate both small and large inhalable particles. We report in this study that the pathogenesis patterns of plague infections caused by the deposition of 1- and 12-microm-particle aerosols of Y. pestis in the lower and upper respiratory tracts (URTs) of mice are different. The median lethal dose for 12-mum particles was 4.9-fold greater than that for 1-microm particles. The 12-microm-particle infection resulted in the degradation of the nasal mucosa and nasal-associated lymphoid tissue (NALT) plus cervical lymphadenopathy prior to bacteremic dissemination. Lung involvement was limited to secondary pneumonia. In contrast, the 1-microm-particle infection resulted in primary pneumonia; in 40% of mice, the involvement of NALT and cervical lymphadenopathy were observed, indicating entry via both URT lymphoid tissues and lungs. Despite bacterial deposition in the gastrointestinal tract, the involvement of Peyer's patches was not observed in either infection. Although there were major differences in pathogenesis, the recombinant F1 and V antigen vaccine and ciprofloxacin protected against plague infections caused by small- and large-particle aerosols.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Ciprofloxacin/administration & dosage , Disease Models, Animal , Plague Vaccine/administration & dosage , Plague , Vaccines, Synthetic/administration & dosage , Yersinia pestis/pathogenicity , Aerosols , Animals , Antibodies, Bacterial/blood , Antigens, Bacterial/administration & dosage , Antigens, Bacterial/genetics , Antigens, Bacterial/immunology , Antigens, Bacterial/metabolism , Female , Humans , Immunization , Lung/microbiology , Lung/pathology , Mice , Mice, Inbred BALB C , Particle Size , Plague/drug therapy , Plague/microbiology , Plague/pathology , Plague/prevention & control , Plague Vaccine/genetics , Plague Vaccine/immunology , Pore Forming Cytotoxic Proteins/administration & dosage , Pore Forming Cytotoxic Proteins/genetics , Pore Forming Cytotoxic Proteins/immunology , Pore Forming Cytotoxic Proteins/metabolism , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/metabolism , Treatment Outcome , Vaccines, Synthetic/immunology , Yersinia pestis/immunology
5.
Appl Environ Microbiol ; 74(20): 6437-43, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18723664

ABSTRACT

The deposition patterns of large-particle microbiological aerosols within the respiratory tract are not well characterized. A novel system (the flow-focusing aerosol generator [FFAG]) which enables the generation of large (>10-microm) aerosol particles containing microorganisms under laboratory conditions was characterized to permit determination of deposition profiles within the murine respiratory tract. Unlike other systems for generating large aerosol particles, the FFAG is compatible with microbiological containment and the inhalational challenge of animals. By use of entrapped Escherichia coli cells, Bacillus atrophaeus spores, or FluoSphere beads, the properties of aerosols generated by the FFAG were compared with the properties of aerosols generated using the commonly available Collison nebulizer, which preferentially generates small (1- to 3-microm) aerosol particles. More entrapped particulates (15.9- to 19.2-fold) were incorporated into 9- to 17-microm particles generated by the FFAG than by the Collison nebulizer. The 1- to 3-microm particles generated by the Collison nebulizer were more likely to contain a particulate than those generated by the FFAG. E. coli cells aerosolized using the FFAG survived better than those aerosolized using the Collison nebulizer. Aerosols generated by the Collison nebulizer and the FFAG preferentially deposited in the lungs and nasal passages of the murine respiratory tract, respectively. However, significant deposition of material also occurred in the gastrointestinal tract after inhalation of both the small (89.7%)- and large (61.5%)-particle aerosols. The aerosols generated by the Collison nebulizer and the FFAG differ with respect to mass distribution, distribution of the entrapped particulates, bacterial survival, and deposition within the murine respiratory tract.


Subject(s)
Aerosols/pharmacokinetics , Inhalation Exposure , Respiratory System/microbiology , Animals , Bacillus/isolation & purification , Colony Count, Microbial , Escherichia coli/isolation & purification , Female , Gastrointestinal Tract/microbiology , Lung/microbiology , Mice , Mice, Inbred BALB C , Microbial Viability , Nasal Cavity/microbiology , Nebulizers and Vaporizers
6.
Int J Exp Pathol ; 89(3): 171-9, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18460069

ABSTRACT

Inhalational anthrax is a rare but potentially fatal infection in man. The common marmoset (Callithrix jacchus) was evaluated as a small non-human primate (NHP) model of inhalational anthrax infection, as an alternative to larger NHP species. The marmoset was found to be susceptible to inhalational exposure to Bacillus anthracis Ames strain. The pathophysiology of infection following inhalational exposure was similar to that previously reported in the rhesus and cynomolgus macaque and humans. The calculated LD(50) for B. anthracis Ames strain in the marmoset was 1.47 x 10(3) colony-forming units, compared with a published LD(50) of 5.5 x 10(4) spores in the rhesus macaque and 4.13 x 10(3) spores in the cynomolgus macaque. This suggests that the common marmoset is an appropriate alternative NHP and will be used for the evaluation of medical countermeasures against respiratory anthrax infection.


Subject(s)
Anthrax/pathology , Bacillus anthracis/pathogenicity , Disease Models, Animal , Respiratory Tract Infections/pathology , Aerosols , Animals , Anthrax/microbiology , Bacillus anthracis/isolation & purification , Body Weight , Callithrix , Colony Count, Microbial , Female , Inhalation Exposure , Lethal Dose 50 , Male , Respiratory Tract Infections/microbiology , Virulence
7.
Infect Immun ; 75(4): 1827-34, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17145938

ABSTRACT

Bacillus anthracis is the causative agent of anthrax, a disease that affects wildlife, livestock, and humans. Protection against anthrax is primarily afforded by immunity to the B. anthracis protective antigen (PA), particularly PA domains 4 and 1. To further the development of an orally delivered human vaccine for mass vaccination against anthrax, we produced Salmonella enterica serovar Typhimurium expressing full-length PA, PA domains 1 and 4, or PA domain 4 using codon-optimized PA DNA fused to the S. enterica serovar Typhi ClyA and under the control of the ompC promoter. Oral immunization of A/J mice with Salmonella expressing full-length PA protected five of six mice against a challenge with 10(5) CFU of aerosolized B. anthracis STI spores, whereas Salmonella expressing PA domains 1 and 4 provided only 25% protection (two of eight mice), and Salmonella expressing PA domain 4 or a Salmonella-only control afforded no measurable protection. However, a purified recombinant fusion protein of domains 1 and 4 provided 100% protection, and purified recombinant 4 provided protection in three of eight immunized mice. Thus, we demonstrate for the first time the efficacy of an oral S. enterica-based vaccine against aerosolized B. anthracis spores.


Subject(s)
Anthrax Vaccines/immunology , Anthrax/prevention & control , Antigens, Bacterial/immunology , Bacillus anthracis/immunology , Bacterial Toxins/immunology , Salmonella typhimurium/genetics , Administration, Oral , Aerosols , Animals , Anthrax/immunology , Anthrax Vaccines/administration & dosage , Anthrax Vaccines/genetics , Antigens, Bacterial/biosynthesis , Antigens, Bacterial/genetics , Bacillus anthracis/genetics , Bacterial Toxins/biosynthesis , Bacterial Toxins/genetics , Disease Models, Animal , Female , Genetic Vectors , Humans , Mice , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Salmonella typhimurium/growth & development , Salmonella typhimurium/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology
8.
Infect Immun ; 74(6): 3687-91, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16714605

ABSTRACT

The identification of Yersinia pestis as a potential bioterrorism agent and the emergence of antibiotic-resistant strains have highlighted the need for improved vaccines and treatments for plague. The aim of this study was to evaluate the potential for ATP-binding cassette (ABC) transporter proteins to be exploited as novel vaccines against plague. Western blotting of ABC transporter proteins using sera from rabbits immunized with killed whole Y. pestis cells or human convalescent-phase sera identified four immunologically reactive proteins: OppA, PstS, YrbD, and PiuA. Mice immunized with these proteins developed antibody to the immunogen. When the immunized mice were challenged with Y. pestis, the OppA-immunized mice showed an increased time to death compared to other groups, and protection appeared to correlate with the level of immunoglobulin G antibody to OppA.


Subject(s)
Bacterial Proteins/immunology , Carrier Proteins/immunology , Lipoproteins/immunology , Plague Vaccine/immunology , Adjuvants, Immunologic/pharmacology , Animals , Antibodies, Bacterial/blood , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Female , Immune Sera/immunology , Immunization , Immunoglobulin G/classification , Mice , Mice, Inbred BALB C , Plague/prevention & control , Yersinia pestis/immunology
9.
J Med Microbiol ; 52(Pt 12): 1109-1115, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14614070

ABSTRACT

The object of this study was to develop and characterize experimental Burkholderia mallei aerosol infection in BALB/c mice. Sixty-five mice were infected with 5000 [approx. 2.5 median lethal doses (MLD)] B. mallei strain ATCC 23344(T) bacteria by the aerosol route. Bacterial counts within lung, liver, spleen, brain, kidney and blood over 14 days were determined and histopathological and immunocytochemical profiles were assessed. Mortality due to B. mallei infection occurred between days 4 and 10 post-infection. Bacterial numbers were consistently higher in the lungs than in other tissues, reaching a maximum of approximately 1.0 x 10(6) c.f.u. ml(-1) at 5 days post-infection. Bacterial counts in liver and spleen tissue remained approximately equal, reaching a maximum of approximately 1.0 x 10(4) c.f.u. ml(-1) at day 4 post-infection. By day 14 post-infection, bacterial counts were in the range 1.0 x 10(3)-1.0 x 10(4) c.f.u. ml(-1) for all tissues. Infection of the lungs by B. mallei resulted in foci of acute inflammation and necrosis. As infection progressed, the inflammatory process became subacute or chronic; this was associated with the development of extensive consolidation. Lesions in liver and spleen tissue were typical of those that might be expected in bacteraemia or bacterial toxaemia. These results suggest that the BALB/c mouse is susceptible to B. mallei when delivered by the aerosol route and that this represents a model system of acute human glanders that is suitable for research into the pathogenesis of and vaccines against this disease.


Subject(s)
Burkholderia Infections/pathology , Aerosols , Animals , Antigens, Bacterial/analysis , Burkholderia Infections/metabolism , Burkholderia Infections/microbiology , Burkholderia mallei , Colony Count, Microbial , Disease Models, Animal , Female , Immunohistochemistry , Lung/pathology , Mice , Mice, Inbred BALB C
10.
Infect Immun ; 71(4): 2234-8, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12654847

ABSTRACT

Monoclonal antibodies specific for Yersinia pestis V antigen and F1 antigen, administered singly or in combination, protected mice in models of bubonic and pneumonic plague. Antibodies showed synergy when administered prophylactically and as a therapy 48 h postinfection. Monoclonal antibodies therefore have potential as a treatment for plague.


Subject(s)
Antibodies, Bacterial/administration & dosage , Antibodies, Monoclonal/administration & dosage , Antigens, Bacterial/immunology , Bacterial Proteins/immunology , Plague/prevention & control , Plague/therapy , Yersinia pestis/immunology , Animals , Antibodies, Bacterial/therapeutic use , Antibodies, Monoclonal/therapeutic use , Disease Models, Animal , Drug Synergism , Drug Therapy, Combination , Humans , Mice , Mice, Inbred BALB C , Pore Forming Cytotoxic Proteins , Yersinia pestis/pathogenicity
SELECTION OF CITATIONS
SEARCH DETAIL